Medical technology company Sensodetect reports net sales of SEK 1.3 million in the first quarter of 2026. Net profit amounted to SEK -1.9 million. Since the group was not established during the corresponding period of the previous year, there are no comparative figures for earlier periods.The company says the quarter was marked by changes in the board of directors and measures to strengthen governance and information disclosure. At the same time, focus has been placed on screening solutions, international expansion and scalable business models, especially in the Middle East.Revenue consisted largely of royalty income from the collaboration with Beijing Haierxi Medical Technology. Operating expenses amounted to SEK -4.1 million and were, according to the company, affected by the establishment in China and Hong Kong.After the end of the period, Sensodetect has, among other things, entered into a non-binding Letter of Intent with a healthcare provider in the UAE regarding a potential pilot collaboration within objective ADHD screening. The company has also paused the ASD study in Saudi Arabia to prioritize more commercially scalable screening solutions.CEO PA Hedin says the company continues the transition toward a more commercially focused operation with priority given to areas with clear market potential and long-term scalability.Separately, it is stated that the board, in light of an indication that the company’s equity could fall below half of the registered share capital, has drawn up a balance sheet for liquidation purposes as of 30 April.The balance sheet, which was considered and approved by the board on 27 May, has been reviewed by the company’s auditor and shows that the company’s adjusted equity exceeds 50 percent of the registered share capital.The board has therefore assessed that there is no obligation to convene the first control meeting.Sensodetect, SEK millionQ1 2026Q1 2025Net sales1.3-Profit before tax-1.9-Net profit-1.9-Earnings per share-0.004-0.02